Business context and reporting period
RadNet, Inc. filed this Form 10-K for the fiscal year ended December 31, 2020. The company operates freestanding outpatient diagnostic imaging centers and related imaging software and AI businesses. At year-end it operated 331 centers in seven states. The filing is an annual report, not a standalone fourth-quarter report.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Total service and capitation revenue | $1,071.8 million | $1,154.2 million |
| Provider relief funding recognized | $26.3 million | — |
| Net loss attributable to RadNet common stockholders | $14.8 million; $0.29 loss per share | $14.8 million income; $0.30 per share |
| Operating income | $35.7 million; 3.3% of revenue | $69.9 million; 6.1% |
| Adjusted EBITDA (non-GAAP) | $139.5 million | $164.1 million |
| Cash provided by operating activities | $233.8 million | $104.3 million |
| Free cash flow (non-GAAP) | $14.0 million | $47.4 million |
| Cash and cash equivalents at year-end | $102.0 million | $40.2 million |
Revenue declined 7.1%. Separately, same-center revenue including provider relief funding was down 5.0%; same-center procedure volume fell approximately 12.3%. Net income for the consolidated group was a loss of $1.7 million, before $13.1 million attributable to noncontrolling interests. The company reported a $0.9 million income-tax provision despite a pretax loss.
At year-end, term debt had a face value of $662.4 million and a carrying value of $652.7 million after debt discount. Cash and available undrawn revolving credit included $102.0 million cash, $187.7 million available on the Barclays revolver and $30.0 million available on the SunTrust revolver. Working capital, excluding current operating lease liabilities, was negative $61.9 million. Operating lease liabilities totaled $528.9 million; finance lease liabilities were $3.3 million. The company reported compliance with its credit-facility covenants.
Material changes versus the prior comparable period
- COVID-19 reduced procedure volumes and revenue; management said volumes recovered to about 90% of pre-pandemic levels in the third quarter and remained consistent through the fourth quarter.
- Operating expenses fell 2.0% to $1,062.4 million, including lower salaries following furloughs and payroll reductions. Depreciation and amortization rose 7.7%, and impairment and severance charges were $4.2 million and $4.4 million, respectively.
- Adjusted EBITDA fell by $24.7 million. Free cash flow declined, despite higher operating cash flow; that cash-flow figure included favorable working-capital movements, including increased deferred revenue and accrued liabilities.
- Cash rose to $102.0 million, while term debt carrying value declined to $652.7 million. The Barclays revolver capacity was increased to $195.0 million in August 2020.
- RadNet acquired DeepHealth for stated consideration of approximately $34.6 million, acquired imaging facilities including eight centers in the Phoenix area, and exited its Imaging On Call teleradiology operations. It ended the year with four fewer centers than in 2019.
Outlook, management commentary, risks and unusual items
Management said the pandemic’s duration and financial effects remained uncertain and that future procedure volumes could be adversely affected. No numerical earnings or revenue guidance is provided in the supplied filing text. Management described the vaccine rollout as a positive development and said it expected a return toward normal operations as vaccination and other mitigation measures progressed.
- COVID-19 support and repayment obligations: RadNet recognized $26.3 million of Provider Relief Fund distributions as revenue. It also received approximately $43.2 million in accelerated Medicare payments and $5.0 million in insurer advances, recorded as deferred revenue and subject to repayment or offsets. The company reported $16.3 million of deferred employer Social Security taxes. It recognized a $4.0 million gain after qualifying for forgiveness of PPP loans.
- Debt and interest-rate exposure: Debt is substantial and primarily variable-rate. A 1% increase in relevant rates was estimated to increase annual interest expense by approximately $6.1 million on the first-lien term loans and $0.5 million on the SunTrust term loan, before considering the stated hedge effects. The filing reports a $2.5 million 2020 expense from the ineffective portion of interest-rate swaps.
- Reimbursement and operating risks: The company cited potential Medicare reimbursement reductions, capitation utilization risk, dependence on physician referrals and contracted radiology groups, competition, and high fixed costs. Healthcare regulatory compliance, professional-practice arrangements, privacy and cybersecurity, and facility accreditation are also material risks.
- Accounting and contingencies: RadNet wrote off $4.2 million of trade names it ceased using. It reported no other impairment from its 2020 annual goodwill test. The company said ordinary-course legal matters were not expected to have a material adverse effect, while noting outcomes are uncertain.
- Subsequent events: RadNet completed additional New York-area acquisitions in January and February 2021 for approximately $53.4 million and received $6.2 million of CARES Act distribution funds in March 2021.
Most important facts for investors to verify
- Whether procedure volumes and same-center revenue recovered after year-end, and how much of reported revenue or cash flow depended on temporary pandemic support and timing effects.
- The repayment and offset schedule for accelerated Medicare and insurer advances, and compliance with Provider Relief Fund terms, including potential recoupment.
- Debt maturities, covenant headroom, variable-rate exposure, hedge accounting effects and the company’s ability to refinance or repay the large 2023 term-loan maturity.
- Whether acquisition integration and DeepHealth’s AI products generate the expected growth and returns, and whether subsequent acquisitions add to leverage or integration risk.
- How Medicare reimbursement changes, referral relationships, capitation costs and cybersecurity or regulatory matters affect margins and cash generation.